Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 7/20 | 0.34 |
| ▸ | PPARG | P37231 | 7/20 | 0.34 |
| ▸ | APLNR | P35414 | 4/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470416 | 0.88 | CMA1 (0.35) | AGTR1PPARGAPLNRCMA1 | |
| SCHEMBL4470424 | 0.88 | CMA1 (0.35) | AGTR1PPARGAPLNRCMA1 | |
| SCHEMBL4486655 | 0.83 | CCR2 (0.33) | AGTR1PPARGCMA1 | |
| SCHEMBL4486658 | 0.83 | CCR2 (0.33) | AGTR1PPARGCMA1 | |
| SCHEMBL4470734 | 0.82 | RAB9A (0.34) | KDM4EMAOB | |
| SCHEMBL4470739 | 0.82 | RAB9A (0.34) | KDM4EMAOB | |
| SCHEMBL4480042 | 0.82 | AGTR1 (0.37) | AGTR1PPARGAPLNRCMA1KDM4E | |
| SCHEMBL4476919 | 0.82 | KCNA5 (0.33) | AGTR1PPARGCMA1KDM4E | |
| SCHEMBL4475959 | 0.82 | POLB (0.36) | AGTR1PPARGCMA1KDM4E | |
| SCHEMBL4476927 | 0.82 | KCNA5 (0.33) | AGTR1PPARGCMA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | AGTR1 227/4885PPARG 1174/4885APLNR 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.